Metffil G1 Tablet is a combination oral hypoglycemic agent containing Glimepiride 1mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. This synergistic combination effectively targets multiple pathophysiological defects in type 2 diabetes, aiding in the reduction of fasting and postprandial blood glucose levels. Metffil G1 is recommended as an adjunct to diet and exercise when monotherapy with either agent is insufficient to achieve adequate glycemic control. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia, as Metformin carries a risk of lactic acidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, while hypoglycemia risk is primarily associated with Glimepiride. Patient education on adherence, lifestyle modification, and recognition of hypoglycemia symptoms is crucial for optimal therapeutic outcomes.